These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 19850587)

  • 21. Effects of enoxaparin preparations on thrombin generation and their correlation with their anti-FXa activity.
    Altman R; Scazziota AS; Pons S; Herrera L; Keller AG; Assefi AR; Di Girolamo G
    Curr Med Res Opin; 2011 Jan; 27(1):1-9. PubMed ID: 21083516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
    Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
    Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
    J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
    Anderson JA; Hirsh J; Yusuf S; Johnston M; Afzal R; Mehta SR; Fox KA; Budaj A; Eikelboom JW
    J Thromb Haemost; 2010 Feb; 8(2):243-9. PubMed ID: 19943881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
    Samama MM; Cohen AT; Darmon JY; Desjardins L; Eldor A; Janbon C; Leizorovicz A; Nguyen H; Olsson CG; Turpie AG; Weisslinger N
    N Engl J Med; 1999 Sep; 341(11):793-800. PubMed ID: 10477777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit.
    Dempfle CE; Lorenz S; Smolinski M; Wurst M; West S; Houdijk WP; Quintel M; Borggrefe M
    Crit Care Med; 2004 Feb; 32(2):520-4. PubMed ID: 14758173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
    Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
    Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Changes in Antithrombin Activity Over Time With Responsiveness to Enoxaparin Prophylaxis and Risk of Trauma-Related Venous Thromboembolism.
    Vincent LE; Talanker MM; Butler DD; Zhang X; Podbielski JM; Wang YW; Chen-Goodspeed A; Hernandez Gonzalez SL; Fox EE; Cotton BA; Wade CE; Cardenas JC
    JAMA Surg; 2022 Aug; 157(8):713-721. PubMed ID: 35731524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
    Tran AH; Lee G
    Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles.
    Cvirn G; Wagner T; Juergens G; Koestenberger M
    Blood Coagul Fibrinolysis; 2009 Jan; 20(1):71-7. PubMed ID: 20339323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels.
    Saw J; Kereiakes DJ; Mahaffey KW; Applegate RJ; Braden GA; Brent BN; Brodie BR; Groce JB; Levine GN; Leya F; Moliterno DJ
    Thromb Res; 2003; 112(5-6):301-6. PubMed ID: 15041274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
    Perzborn E; Strassburger J; Wilmen A; Pohlmann J; Roehrig S; Schlemmer KH; Straub A
    J Thromb Haemost; 2005 Mar; 3(3):514-21. PubMed ID: 15748242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clexane in prevention of acute venous thrombosis and pulmonary thromboembolism].
    Kirienko AI; Zolotukhin IA
    Ter Arkh; 1998; 70(11):78-80. PubMed ID: 9949471
    [No Abstract]   [Full Text] [Related]  

  • 39. Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients.
    Arnold JD; Dart BW; Barker DE; Maxwell RA; Burkholder HC; Mejia VA; Smith PW; Longley JM
    Am Surg; 2010 Jun; 76(6):563-70. PubMed ID: 20583509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.
    Agnelli G; Haas S; Ginsberg JS; Krueger KA; Dmitrienko A; Brandt JT
    J Thromb Haemost; 2007 Apr; 5(4):746-53. PubMed ID: 17408408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.